001053910 001__ 1053910
001053910 005__ 20260130172304.0
001053910 0247_ $$2doi$$a10.1093/neuonc/noaf201.1161
001053910 0247_ $$2ISSN$$a1522-8517
001053910 0247_ $$2ISSN$$a1523-5866
001053910 037__ $$aFZJ-2026-01608
001053910 082__ $$a610
001053910 1001_ $$0P:(DE-HGF)0$$aMair, Maximilian J$$b0
001053910 1112_ $$a7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies$$cHonolulu$$d2025-11-20 - 2025-11-23$$gSNO / WFNOS 2025$$wUSA
001053910 245__ $$aIMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey
001053910 260__ $$c2025
001053910 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1769790008_27930
001053910 3367_ $$033$$2EndNote$$aConference Paper
001053910 3367_ $$2BibTeX$$aINPROCEEDINGS
001053910 3367_ $$2DRIVER$$aconferenceObject
001053910 3367_ $$2DataCite$$aOutput Types/Conference Abstract
001053910 3367_ $$2ORCID$$aOTHER
001053910 520__ $$aAbstractBACKGROUNDPositron emission tomography (PET) is increasingly used in patients with brain tumors, yet its adoption varies across institutions.METHODSTo assess the current landscape, a cross-sectional survey was conducted among European Organization for Research and Treatment of Cancer (EORTC) – Brain Tumour Group (BTG) sites between June 2024 and August 2024.RESULTSOut of the 312 sites invited, 103 replies from 20 countries in the Europe/Middle East region were received. PET availability was reported by 96/103 (93.2%) sites, of whom 74 reported PET use in patients with brain tumors. Most frequently, PET was performed in glioma (69/74, 93.2%), followed by brain metastasis (58/74, 78.4%), meningioma (52/74, 70.3%), and CNS lymphoma (46/74, 62.2%). Amino acid PET was used at 62/71 centers (87.3%), mainly in glioma (58/59, 98.3%) and for differentiation of tumor progression from treatment-related changes (58/59, 98.3%), differential diagnosis (54/59, 91.5%), and hotspot delineation (47/59, 79.7%). Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%), predominantly in meningioma (48/49, 98.0%), and for patient selection before radioligand therapy (41/49, 83.7%) as well as for target volume definition in radiotherapy (33/49, 67.3%) and differential diagnosis (27/49, 55.1%). PET was covered by statutory health insurance at 46/59 (78.0%) centers for amino acid PET and 33/49 (67.3%) for SSTR PET according to self-reported information. Main reasons for not performing PET in clinical routine included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET considered unnecessary by referring physicians (8/29, 27.6%).CONCLUSIONPET is widely used among EORTC-BTG sites, although implementation varies and is influenced by factors such as tracer availability, cost, and institutional perceptions. While further data from broader surveys including non-academic institutions is needed, the findings support the implementation of PET as clinical trial endpoint.
001053910 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001053910 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001053910 7001_ $$aLohmann, Philipp$$b1
001053910 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b2$$ufzj
001053910 7001_ $$0P:(DE-HGF)0$$aBelting, Mattias$$b3
001053910 7001_ $$0P:(DE-HGF)0$$aBrandal, Petter$$b4
001053910 7001_ $$0P:(DE-HGF)0$$aBroen, Martinus P G$$b5
001053910 7001_ $$0P:(DE-HGF)0$$aCicone, Francesco$$b6
001053910 7001_ $$0P:(DE-HGF)0$$aDaisne, Jean-François$$b7
001053910 7001_ $$0P:(DE-HGF)0$$aDucray, François$$b8
001053910 7001_ $$0P:(DE-HGF)0$$aEhret, Felix$$b9
001053910 7001_ $$0P:(DE-HGF)0$$aFurtner, Julia$$b10
001053910 7001_ $$0P:(DE-HGF)0$$aJakola, Asgeir S$$b11
001053910 7001_ $$0P:(DE-HGF)0$$aNiyazi, Maximilian$$b12
001053910 7001_ $$0P:(DE-HGF)0$$aPellerino, Alessia$$b13
001053910 7001_ $$0P:(DE-HGF)0$$aRasschaert, Marika$$b14
001053910 7001_ $$0P:(DE-HGF)0$$aRazis, Evangelia$$b15
001053910 7001_ $$0P:(DE-HGF)0$$aSahm, Felix$$b16
001053910 7001_ $$0P:(DE-HGF)0$$aSmits, Marion$$b17
001053910 7001_ $$0P:(DE-HGF)0$$aTolboom, Nelleke$$b18
001053910 7001_ $$0P:(DE-HGF)0$$aVerger, Antoine$$b19
001053910 7001_ $$0P:(DE-HGF)0$$aLe Rhun, Emilie$$b20
001053910 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b21
001053910 7001_ $$0P:(DE-HGF)0$$aWeller, Michael$$b22
001053910 7001_ $$0P:(DE-HGF)0$$aPreusser, Matthias$$b23
001053910 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b24
001053910 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf201.1161$$gVol. 27, no. Supplement_5, p. v292 - v293$$x1523-5866$$y2025
001053910 8564_ $$uhttps://academic.oup.com/neuro-oncology/article/27/Supplement_5/v292/8319344
001053910 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b2$$kFZJ
001053910 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001053910 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001053910 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001053910 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053910 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
001053910 980__ $$aabstract
001053910 980__ $$aEDITORS
001053910 980__ $$aVDBINPRINT
001053910 980__ $$aI:(DE-Juel1)INM-4-20090406
001053910 980__ $$aUNRESTRICTED